BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress
June 12, 2020 02:30 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma
June 03, 2020 07:15 ET | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 03, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
May 29, 2020 08:00 ET | BeiGene, LTD.
- Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VGPR...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
May 21, 2020 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China and PETACH TIKVA, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
May 20, 2020 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 15, 2020 07:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
May 14, 2020 09:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Reports First Quarter 2020 Financial Results
May 11, 2020 16:05 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 11, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
April 29, 2020 17:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
April 20, 2020 16:05 ET | BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...